

Medicines Procurement and Supply Chain

NHS England

2nd Floor, Rutland House

Runcorn

Cheshire

WA7 2ES

**All messages regarding the offer documentation should**

**be sent via the Atamis Website:**

health.atamis.co.uk

16 February 2024

**Invitation to offer for NHS National Framework for Transition products commencing 1 May 2024**

**Offer reference number: CM/TNS/05/2024**

**Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months.**

**Potential periods of call-offs under the framework agreement:**

**CM/TNS/05/2024/01 - Dimethyl fumarate, Teriflunomide, Trabectedin**

**Lot 1   NWLN:          01/05/2024 to 31/01/2025 (9 months)**

**Lot 2   CESW:          01/05/2024 to 30/09/2025 (17 months)**

**Lot 3   LSNE:           01/05/2024 to 30/09/2025 (17 months)**

**CM/TNS/05/2024/02 - Apixaban, Sapropterin**

**Lot 1   DNW+DNE+DCE     01/05/2024 to 30/09/2025 (17 months)**

**Lot 2   DLS+DLN+DSW      01/05/2024 to 30/09/2025 (17 months)**

**Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England**

Please be reminded that **from the 1st of January 2024 to be successfully awarded in any MVA tenders you will need to have submitted an Evergreen assessment on the Atamis portal.**

The requirement to submit an Evergreen assessment is on a pass/fail basis. Therefore, if you have not submitted an evergreen assessment at the time of bid submission you will not be able to gain a place on an NHSE medicines framework or contract.

For further information on the policy requirements [please click here.](https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.sps.nhs.uk%2Farticles%2Fnet-zero-and-social-value-requirements-in-nhse-medicines-tenders%2F&data=05%7C01%7Ckatie.noonan%40nhs.net%7Cf237574ba54c4a331f0308dbf5b65d1b%7C37c354b285b047f5b22207b48d774ee3%7C0%7C0%7C638373935804650535%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=auE2KJVbABhLa%2Fo3X3LUJDzha4wdRdN0zJq99Y5aKBI%3D&reserved=0)

(Link: <https://www.sps.nhs.uk/articles/net-zero-and-social-value-requirements-in-nhse-medicines-tenders/> )

For further technical information on submitting your Evergreen assessment [please click here.](https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.england.nhs.uk%2Fnhs-commercial%2Fcentral-commercial-function-ccf%2Fevergreen%2F&data=05%7C01%7Ckatie.noonan%40nhs.net%7Cf237574ba54c4a331f0308dbf5b65d1b%7C37c354b285b047f5b22207b48d774ee3%7C0%7C0%7C638373935804806725%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=zYUcIxjPcvkcHkZNmr8EEr%2FkdP%2FYy4h5VKoLY2Db1Ns%3D&reserved=0)

(Link: <https://www.england.nhs.uk/nhs-commercial/central-commercial-function-ccf/evergreen/> )

Bidders should engage internally to ensure that the Atamis account used to submit the bid also includes the active Evergreen assessment, rather than a separate / duplicate account. Failure to have an active Evergreen assessment on the Atamis account used to submit the bid, may result in the bid being non-compliant and the bidder being excluded from further participation in the procurement process.

**Within the framework document, the relevant clauses are contained in Schedule 1 Section 8.**

NHS England (‘Authority’) invites offers for the above-mentioned goods and/or services as defined in Document No.03 Framework Agreement and Terms and Conditions.

Offers shall be made subject to the terms of:

Document No. 01 Invitation to Offer Letter

Document No. 02 Terms of offer

Document No. 03 Framework Agreement and Terms and Conditions

Document No. 04a Quality Assurance Process

Document No. 04b Assessment Criteria, Stability Protocol and Additional Specification Requirements

Document No. 05 Selectt offer schedule instructions

Document No. 05a(i) Selectt offer schedule – CM/TNS/05/2024/01: NWLN, CESW & LSNE

Document No. 05a(ii) Selectt offer schedule – CM/TNS/05/2024/02: DNW+DNE+DCE & DLS+DLN+DSW

Document No. 05b(i) Tender Product Listing & Usage – CM/TNS/05/2024/01: NWLN, CESW & LSNE

Document No. 05b(ii) Tender Product Listing & Usage – CM/TNS/05/2024/02: DNW+DNE+DCE & DLS+DLN+DSW

Document No. 05c - Contract technical specification CM-TNS-05-2024

Document No. 06 Form of offer

Document No. 07a Quality control technical sheet

Document No. 07b Quality Assurance Policy to support the National

Document No. 08 Confidential information schedule

Document No. 09 Participating Authorities

all of which constitute this Invitation to offer.

If any of the documents constituting the Invitation to offer is missing please contact the undersigned immediately via the Atamis messaging portal.

The Authority does not bind itself to accept the lowest offer or any offer at all and reserves the right to accept an offer either in whole or in part, each item being for this purpose treated as offered separately. The Authority reserves the right to conclude a framework agreement for the supply of the goods and/or services with more than one Offeror.

I would like to draw your attention to the following important points when completing and submitting your offer:

1. All offers must be written in English.

2. All offers must be submitted subject to and in accordance with the documentation comprising the Invitation to offer. Save where the Offerors are instructed to provide information, the documentation comprising the Invitation to offer must not be amended in any way.

3. All offers must be loaded onto the Medicines Procurement and Supply Chain’s eTendering portal health.atamis.co.uk

4. Offers must be open for 90 days.

5. Offers must be fully completed and available on the designated website no later than **13:00** on **Monday 18 March 2024.**

I must also draw your attention to the enclosed Form of offer where all the requirements for completing and submitting an offer can be found. Failure to comply with these instructions may result in your offer being rejected.

I hope that the above instructions are clear but please contact the undersigned via the Atamis messaging portal if there is anything you wish to clarify.

Yours sincerely,



Katie Noonan

Sourcing Specialist

Branded, Biosimilars and IV Fluids Procurement Support